SCHEMBL22096040

SCHEMBL22096040

COC(=O)c1nonc1NCn1nnnc1-c1cccc(C(F)(F)F)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STAT5B P51692 3/20 0.55
POLB P06746 1/20 0.48
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
IDO1 P14902 1/20 0.41
HTT P42858 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
XPO1 O14980 1/20 0.39
SLC6A2 P23975 1/20 0.39
SLC6A4 P31645 1/20 0.39
SLC6A3 Q01959 1/20 0.39
MAPT P10636 1/20 0.38
GRIN1 Q05586 2/20 0.37
GRIN2B Q13224 2/20 0.37
RXFP1 Q9HBX9 1/20 0.37
CACNA1B Q00975 1/20 0.37
APBA1 Q02410 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
CYP1A2 P05177 1/20 0.36
CYP2C19 P33261 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22096043 0.90 STAT5B (0.68) STAT5BPOLBKMT2AIDO1HTT
SCHEMBL22096019 0.90 STAT5B (0.62) STAT5BMEN1KMT2AIDO1HTT
SCHEMBL22096042 0.88 STAT5B (0.54) STAT5BPOLBL3MBTL1
SCHEMBL22096041 0.87 STAT5B (0.56) STAT5BMEN1KMT2AIDO1CYP1A2
SCHEMBL22096017 0.86 STAT5B (0.65) STAT5BPOLBHTTCYP1A2CYP2C19
SCHEMBL22096044 0.82 STAT5B (0.51) STAT5BPOLBCYP1A2CYP2C19
SCHEMBL22096023 0.80 STAT5B (0.65) STAT5BPOLBIDO1
SCHEMBL22096024 0.77 STAT5B (0.79) STAT5BPOLBMEN1KMT2AHTT
SCHEMBL8947234 0.76 POLB (0.60) POLBMEN1KMT2AHTTL3MBTL1
SCHEMBL22096016 0.76 STAT5B (0.81) STAT5BPOLBHTTCYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10683286-B2 Furazan-3-carboxylic acid derivatives and use thereof in treatment of cancer FREIE UNIVERSITAET BERLIN (DE) 2020-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10683286-B2 Furazan-3-carboxylic acid derivatives and use thereof in treatment of cancer FLT3, MCL1, MYD88 STAT5B 59/4885POLB 4594/4885MEN1 2599/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.